Objective To observe the inhibition effect of recombinant human monocyte chemoattractant protein－ 1(MCP－ 1) on implantation and growth of human osteosarcoma cells. Methods The method of protein fusion was used for the expression of MCP－ 1 in b.coli and then the MCP－ 1 was extracted and purified. Fifty nude mice were divided into 10 groups. For A1－ 4 groups, the 5 mice in each group were locally injected with doses of 1? g, 10? g, 100? g, 1 mg of MCP－ 1 at the same time when 4.4? 106 osteosarcoma cells were implanted in vivo. For B0－ 4 groups, 5 mice in each group, the injection were given 2 weeks later when there was the formation of the tumor mass at doses of 0? g(0.2 ml normal saline), 1? g, 10? g, 100? g, 1 mg of MCP－ 1 every other day. Five mice in group C were injected with dose of 0.2 ml NS as control. Results Implantation of osteosarcoma cells were completely prevented among mice of group A2－ 4, tumor inhibiting effect even in group A1 and the rate of tumor inhibition was 69.69％ . AKP values in mice of group A1－ 4 were much lower than those of group B0(P

Objective To study the effect of vascular endothelial growth factor (VEGF) containing fibrin glue(FG) on re-endotheliazation, cell proliferation and intimal hyperplasia in a canine model of carotid artery endothelium injury. MethodsThe effect of FG/VEGF/heparin versus FG alone treatment was evaluated at the time point of 10, 30, and 90 days by measuring the intima/media (I/M) ratio and cell proliferation by BrdU incorporation using immunohistochemistry. EC coverage was determined by SEM. ResultsCompared with normal saline control, FG/VEGF/heparin treatment significantly increased EC coverage at day 10 and at day 30 (P

OBJECTIVE To systematically evaluate the efficacy and safety of compound danshen preparations combined with conventional chemical drug treatment for peptic ulcer （PU）， providing evidence-based guidance for clinical treatment of PU. METHODS Related clinical randomized controlled trials were collected from CNKI， VIP， Wangfang data， CBM， PubMed， Embase and Web of Science from their establishment date to September 30， 2023. The qualities of included literature were evaluated by Cochrane Systematically Evaluator Manual 5.1.0. Meta-analysis， sensitivity analysis and publication bias analysis were conducted with RevMan 5.3 software. RESULTS Totally 26 pieces of literature were included with total of 2 451 cases， including 1 243 cases in trial group （compound danshen preparations+conventional chemical drug treatment） and 1 208 cases in the control group （conventional chemical drug treatment）. In terms of effectiveness， trial group had significant advantages in ulcer healing rate [OR＝4.66， 95%CI （3.53， 6.15）， P＜0.000 01]， HP eradication rate [OR＝1.90， 95%CI （1.12， 3.22）， P＝0.02]，and pain relief rate [OR＝3.91， 95%CI （2.31， 6.61）， P＜0.000 01] than control group， while ulcer recurrence rate [OR＝0.22， 95%CI （0.15， 0.32）， P＜0.000 01] and serum levels of pepsinogen （PG）Ⅰ [SMD＝－1.92， 95%CI （－2.25， －1.58）， P＜0.000 01]， PGⅡ [SMD＝－3.88， 95%CI （－4.35， －3.41）， P＜0.000 01] and G-17 [SMD＝－3.44， 95%CI （－3.87， －3.00）， P＜0.000 01] were significantly lower than control group. In terms of safety， the main adverse reactions were abdominal discomfort， headache， dizziness， dry mouth， facial flushing， etc. There was no significant difference in the incidence of adverse reactionsbetween the two groups [OR＝1.08， 95%CI （0.75， 1.54）， P＝0.69]. Subgroup analysis of ulcer healing rate and HP eradication rate based on dosage form showed that HP eradication rate in the compound danshen pellet group was not significantly improved compared to the control group， with consistent results for the remaining outcomes. The sensitivity analysis showed that above results were stable. There was less possibility of publication bias in this study. CONCLUSIONS Compared with conventional chemical drug treatment alone， the combination of compound danshen preparations can effectively improve the clinical symptoms of PU patients with similar safety.

Since the Guangdong alliance launched the centralized procurement of Chinese patent medicine， manufacturers have engaged in fierce price competition to obtain the qualification for selection. In order to ensure that manufacturers have lowered the price without decreasing quality， the evaluation criteria for the quality of Chinese patent medicine is constructed on the basis of the characteristics of traditional Chinese medicine. The evaluation criteria consist of the production process and therapeutic effect evaluation. The evaluation indicators involve raw materials， processing and clinical use covering the whole life cycle of Chinese patent medicine. The evaluation of production process includes 3 secondary indicators （the quality of traditional Chinese medicine， the quality of traditional Chinese medicine decoction pieces and the quality of Chinese patent medicines） and 13 tertiary indicators （standardized production， quality inspection， processing specifications， technical processes， safety risk control， etc.）， which fully reflect the quality control of key links in the production of Chinese patent medicine. The therapeutic effect evaluation includes 5 secondary indicators （theoretical origin of formulation， proactive research by production enterprises， evidence-based medical evidence， clinical use， and technological embodiment） and 18 tertiary indicators （theoretical sources， post-market effectiveness re- evaluation， clinical guidelines， expert consensus， etc.） to assess the quality and efficacy of Chinese patent medicine from multiple perspectives and levels. This study is a useful supplement to the scheme of centralized procurement of Guangdong alliance， which can not only provide data support for selecting “low-cost and high-quality” Chinese patent medicine， but also provide information reference for hospitals to make procurement decisions.